Skip to main content

Table 2 Comparison of Laboratory Results Before and After the Treatment in Groups (Group 1: Early treatment with FPV and HQ, Group 2: Late treatment with FPV and HQ, Group 3: Treatment with only HQ)

From: Benefits of treatment with favipiravir in hospitalized patients for COVID-19: a retrospective observational case–control study

Changes in variables Group 1 Group 2 Group 3
Mean ± SD p Mean ± SD p Mean ± SD p
CRP 15.2 ± 39.2 0.077 20.2 ± 63.8 0.045 16.2 ± 68.2 0.113
Lymphocyte  − 478.9 ± 930.0 0.066  − 275.5 ± 643.6 0.007 55.1 ± 697.9 0.595
D-Dimer  − 0.74 ± 2.06 0.287  − 0.96 ± 4.71 0.212 0.09 ± 0.63 0.371
Ferritin  − 106.6 ± 280.5 0.287 52.5 ± 254.4 0.276 26.5 ± 487.5 0.739
Cr  − 4.91 ± 8.97 0.052 0.01 ± 0.64 0.902  − 0.68 ± 4.94 0.113
AST 10.4 ± 14.7 0.003 4.2 ± 89.8 0.753 8.2 ± 37.5 0.148
ALT  − 8.2 ± 21.2 0.208  − 4.3 ± 93.7 0.757  − 6.8 ± 28.0 0.101
  1. Statistically significant values are presented in bold. The median values given are the numerical results calculated by the difference of consecutive tests. A negative value means decrease whereas a positive value indicates an increase. The pre and post values of the parameters were compared using the paired sample t test and two-way ANOVA
  2. ALT alanine aminotransferase; AST aspartate aminotransferases; CRP c-reactive protein; Cr creatinin; NS: non-significant